Capricor Therapeutics Q3 net loss widens as expenses rise

Overview

• US biotech reported no Q3 revenue as focus remained on late-stage therapy development

• Q3 operating expenses rose yr/yr, mainly due to pre-commercial and manufacturing scale-up

• Net loss widened in Q3 2026 compared to prior year

Outlook

• Company expects cash resources to fund operations for at least the next 12 months

• Capricor to provide further financial guidance after regulatory clarity on Deramiocel

• Company's outlook excludes potential revenue from product sales or Priority Review Voucher monetization

Result Drivers

• PRE-COMMERCIAL SPENDING - Higher Q3 operating expenses were primarily driven by pre-commercial activities and manufacturing scale-up

• WORKFORCE REDUCTION - Co implemented a workforce reduction in Q3, affecting about 10% of employees to reduce operating expenses and align resources with priorities

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Capricor Therapeutics, Inc. is $18.50, about 87.8% above its November 9 closing price of $9.85

Reuters Recommended Reads

• Nov 10 - Tyra Biosciences Q3 net loss widens on higher R&D costs

• Nov 10 - Corbus Pharmaceuticals Q3 net loss widens on higher expenses

• Nov 10 - Biotech firm PepGen's Q3 net loss widens as R&D expenses rise

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)